Novakand Pharma AB (publ) (STO:NOVKAN)
Sweden · Delayed Price · Currency is SEK 0.1400
+0.0130 (10.24%)
Jan 21, 2026, 5:29 PM CET
Novakand Pharma AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
15.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 90.00K | -3.13M | -97.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alligator Bioscience AB | 46.22M |
| Fluicell AB | 13.20M |
| ExpreS2ion Biotech Holding AB | 10.85M |
| NanoEcho AB | 3.43M |
| Aptahem AB | 2.47M |
| Simris Group AB (PUBL) | 2.30M |
| 2cureX AB | 1.98M |
| Lipigon Pharmaceuticals AB | 1.32M |